99mTc-Oncardia is a target specific sugar analogue radiopharmaceutical specifically developed for use with SPECT and SPECT/CT cameras to image cancer. SPECT cameras are found in over 90% of the world’s hospitals. Prior to 99mTc-Oncardia, the only way to perform a molecular image in cancer was with 18F-FDG used with PET cameras which remain comparatively expensive and found in less than 2% of the world’s hospitals. Cell Theranostics is sponsoring a Phase 3 lung cancer imaging trial for Oncardia under an FDA approved Special Protocol Assessment (SPA). Oncardia offers many advantages over FDG-PET imaging including access, cost, and the ability to monitor therapy during the course of the patient’s therapy.